At Hiroshima University's Graduate School of Biomedical and Health Sciences, researchers have pinpointed something that sounds like molecular geography: a single amino acid marker within the RELA gene that determines whether a mutation will cause disease through shortage or sabotage. This discovery, published in the Journal of Allergy and Clinical Immunology, offers clinicians a map to navigate one of the rarest inflammatory disorders known to medicine.
Autosomal dominant RELA deficiency affects so few people that only 45 individuals from 17 families worldwide have been confirmed with the condition. Yet for each of them, understanding how their particular genetic mutation behaves is crucial to receiving the right treatment. The RELA gene produces a protein essential to immune responses, cell survival, and inflammation control. When one copy of this gene is broken, patients can develop recurring mouth and genital ulcers, intestinal inflammation, and sometimes broader autoinflammatory symptoms that ripple through their entire body.
What made this deficiency particularly puzzling is that not all RELA mutations cause disease in the same way. Some are like a broken machine that simply stops working—a condition called haploinsufficiency, where the body doesn't produce enough functional protein to do its job. Others are like a broken machine that actively sabotages the working one—a dominant-negative effect, where the faulty protein interferes with the normal one and triggers more severe inflammation. The clinical consequences differ sharply. Patients with dominant-negative variants responded poorly to standard corticosteroid treatments and more often needed biologic therapies, particularly anti-TNF drugs. Those with haploinsufficiency could sometimes manage without these more aggressive interventions.
The team, led by professor Satoshi Okada, studied eight patients across five families to find the pattern. They discovered that the boundary between these two different disease mechanisms lies at a single point: amino acid proline at position 290, or P290. "RELA variants with a stop codon located N-terminal to amino acid P290 exhibit haploinsufficiency, whereas RELA variants with a stop codon located C-terminal to P290 exhibit a dominant-negative effect," Okada explained. In practical terms, if the genetic mutation creates an early stop signal before P290, the cell produces little to no usable protein. If the stop signal comes after P290, the cell produces a shortened protein that actively harms its normal partner.
This distinction transforms how clinicians can approach newly diagnosed patients. Instead of discovering which type of mutation a patient carries through time-consuming trial and error—trying one drug, seeing if it works, switching if it doesn't—doctors now have a tool to predict the likely behavior of a mutation based on its location. That means faster diagnosis and earlier deployment of the most appropriate therapy, reducing the painful symptoms that have defined these patients' lives.
Yet the research also reveals its own frontier. Missense mutations, which alter a single amino acid without creating an early stop signal, still defy prediction. Their effects cannot be determined from location alone, requiring laboratory testing case by case. Okada calls this "an unmet challenge and an important priority for future research." For the rare families living with RELA deficiency, each answer to these genetic puzzles brings them closer to more precise, more humane care.